{"entity":{"id":"rinuagene-biotechnology","kind":"company","name":"RinuaGene Biotechnology","aka":["RinuaGene"],"tldr":"RinuaGene develops mRNA medicines. Its lead product, RG002, is a therapeutic vaccine meant to make the immune system clear cervical precancer caused by HPV types 16 and 18, before it can turn into cancer.","summary":"RinuaGene Biotechnology Co., Ltd., in BioBay Industry Park, Suzhou Industrial Park, China, was founded in 2021, according to the company, to develop RNA therapeutics and vaccines on an end-to-end mRNA and lipid nanoparticle platform. Its lead programme RG002 Injection is a therapeutic HPV mRNA vaccine for HPV-associated high-grade squamous intraepithelial lesions, persistent HPV infection and HPV-associated cancers; the company announced US FDA clearance followed by China NMPA CDE IND approval in December 2024. A phase 1/2 study in HPV 16- or 18-associated cervical intraepithelial neoplasia grade 2 or 3 is registered (NCT06273553). Related products RG002-02 to RG002-04 target the same lesions and respiratory papillomatosis, and the company also lists protein-replacement and prophylactic influenza and RSV vaccine programmes. In October 2026 it announced a collaboration with the Medicines Patent Pool under the WHO-led mRNA technology transfer programme. Founded in 2021, according to the company. Its first registered study, NCT06273553, in cervical precancer, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.rinuagene.com/"},{"label":"Pipeline","url":"https://www.rinuagene.com/pipeline/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of RG002 in HPV 16/18 CIN2/3 (NCT06273553)","url":"https://clinicaltrials.gov/study/NCT06273553"}],"tags":[],"related":[],"cancers":["cervical"],"sections":["immunotherapy","prevention"],"technologies":["interception-vaccination"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: rinuagene.com home and pipeline pages and the December 2024 IND release. Financing not stated on the pages read.","RinuaGene is a general mRNA company; it is included because its lead clinical programme treats cervical precancer and is listed for HPV-associated cancer. Its registered study is in precancer (CIN2/3), not invasive cancer, so the cervical cancer link is to the disease being prevented.","Trial facts from the ClinicalTrials.gov record NCT06273553, read on 29 October 2026."],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.rinuagene.com/","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/rinuagene-biotechnology/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/"}]}}